The IMID Forum

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.

Professors discuss groundbreaking studies in Psoriatic Arthritis, focusing on bimekizumab's rapid efficacy for pain and fatigue relief. They delve into long-term results from guselkumab, revealing sustained clinical improvements over two years. The importance of personalized treatment strategies is highlighted, especially concerning the impact of background therapies. They also emphasize patient-reported outcomes, demonstrating how insights into patients' experiences can significantly enhance care and treatment approaches.

Key highlights from the ACR 2024 conference on immune-mediated inflammatory diseases are explored, with a focus on findings related to psoriatic arthritis. The potential of JAK inhibitors, like gazelcomab, is discussed alongside insights into the role of sex differences in medication responses. The impact of central nervous system factors on fatigue in inflammatory diseases is also examined. Emerging treatments like Sonolocumab and advancements in rheumatoid arthritis care are covered, while mental health outcomes related to bimicizumab treatment are analyzed.

Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.

Webinar Highlights Podcast: Join Professor Iain McInnes and Professor Georg Schett as they discuss the recent webinar hosted on the IMID Forum: “CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases”. Listen to them discuss key highlights from the webinar including the development of CAR T-cell therapy, the application of CAR T to autoimmune diseases, and the potential risks and reservations associated with this therapeutic approach.

ACR 2024 Highlights: Day 3 by The Immune-Mediated Inflammatory Disease Forum

The discussion kicks off with a look at the ACR 2024 Congress, spotlighting essential sessions and resources for rheumatologists. Guzelcomab takes center stage as experts reveal its promising role in Psoriatic Arthritis, particularly its effectiveness compared to traditional treatments. Delving deeper, innovations like bimikizumab and secukinamab offer fresh perspectives on therapy options. Revolutionary findings in interstitial lung disease treatments are also highlighted, emphasizing personalized approaches. The potential of biosimilars and the push for early intervention complete the insightful exploration.

ACR 2024 Highlights: Day 2 by The Immune-Mediated Inflammatory Disease Forum

ACR 2024 Highlights: Day 1 by The Immune-Mediated Inflammatory Disease Forum